Clinical trials
Lung Cancer Stage III clinical trials
Below are recruiting lung cancer stage iii clinical trials, each written for real people, not researchers. We’re tracking 392 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06096844RecruitingPhase 3
Chemo plus immunotherapy vs immunotherapy alone for older adults with advanced lung cancer
This trial compares chemotherapy combined with immunotherapy to immunotherapy alone for adults 70 and older with advanced non-small cell lung cancer that has a specific protein level (PD-L1 1-49%). It aims to find which treatment works better for this group.
Fayetteville, ArkansasAges 70 years+ - NCT04589468Recruiting
Exercise for cancer survivors at high risk
This study tests whether a structured exercise program can help prevent cancer from coming back in people who have been treated for certain solid tumors (colorectal, ovarian, lung, or breast cancer). If you've completed surgery and adjuvant therapy within the past 2 years and are currently not exercising much, you may be eligible. Participation involves following an exercise plan and regular check-ins.
Durate, CaliforniaAges 18 years+ - NCT07322341RecruitingPhase 2
Study of SX-682 with atezolizumab for advanced lung cancer
This trial tests a new drug combination (SX-682 plus atezolizumab) for people with advanced non-small cell lung cancer that has grown after standard treatments like immunotherapy and chemotherapy. It aims to see if the combination can help shrink or slow the cancer.
Seattle, WashingtonAges 18 years+ - NCT07195734RecruitingPhase 2
Adding chemo or immunotherapy before surgery for advanced head and neck cancer
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
Tucson, ArizonaAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT06122064Recruiting
Tool to help lung cancer patients decide on adjuvant treatment
This study is testing a tool to help you and your doctor make decisions together about whether to have extra treatment after surgery for non-small cell lung cancer (stage 1B or higher). It only includes patients at Mayo Clinic in Rochester who are eligible for that extra treatment.
Rochester, MinnesotaAges 18 years+ - NCT07619313RecruitingPhase 1
AB801 with Chemotherapy and Immunotherapy for Bile Duct or Pancreatic Cancer
This study tests a new drug called AB801 combined with standard chemotherapy and immunotherapy for advanced bile duct cancer (cholangiocarcinoma) or pancreatic cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
Los Angeles, CaliforniaAges 18 years+ - NCT07191717RecruitingPhase 2
Imlunestrant and abemaciclib for early ER+ breast cancer
This trial tests whether adding two targeted drugs, imlunestrant and abemaciclib, to your usual hormone therapy can lower the chance of your breast cancer coming back. It is for people with early-stage ER+ breast cancer who have no signs of cancer on scans but have tiny amounts of tumor DNA in their blood (called ctDNA).
Los Angeles, CaliforniaAges 18 years+ - NCT07017829RecruitingPhase 2
Combination therapy for STK11-mutant lung cancer
This trial tests a new drug (GT103) combined with the approved immunotherapy drug pembrolizumab for people with advanced lung cancer that has a specific genetic change (STK11). The goal is to see if adding GT103 helps control the cancer better than pembrolizumab alone.
Buffalo, New YorkAges 18 years+ - NCT06980038RecruitingPhase 2
Testing two immunotherapy drugs before surgery for advanced head and neck cancer
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
Irvine, CaliforniaAges 18 years+ - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Phoenix, ArizonaAges 18 years+ - NCT07489066RecruitingPhase 2
Study of PF-08634404 for early-stage or locally advanced lung cancer
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
Huntsville, AlabamaAges 18 years+ - NCT07251582RecruitingPhase 3
Comparing infusion timing for lung cancer immunotherapy before surgery
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
Changsha, HunanAges 18–75 - NCT07761910RecruitingPhase 2
Study of heart effects of radiation therapy using PET-CT for stage III lung cancer
This study looks at whether PET-CT scans can help detect heart damage caused by radiation therapy in patients with stage III lung cancer. If you're getting chemotherapy and radiation together, you may participate to help doctors find ways to reduce heart risks.
Indianapolis, IndianaAges 18 years+ - NCT06656598RecruitingPhase 2
Adjuvant treatment for elderly or unfit patients with stage III lung cancer
This trial tests whether adding an immunotherapy drug called cemiplimab to chemotherapy, followed by radiation, can help older or less fit patients with stage III lung cancer. The goal is to see if this combination improves outcomes compared to usual care.
AngersAges 18 years+ - NCT07541170RecruitingPhase 3
Testing divarasib after lung cancer surgery and chemotherapy
This study tests whether a drug called divarasib can help prevent lung cancer from coming back after surgery and initial treatment. You would only qualify if your cancer has a specific genetic mutation (KRAS G12C) and you've already had surgery and chemotherapy with immunotherapy.
Clovis, CaliforniaAges 18 years+ - NCT07361497RecruitingPhase 3
New Drug vs Standard Drug After Chemoradiation for Stage 3 Lung Cancer
This study tests a new drug, pumitamig, against an older drug, durvalumab, for people with stage 3 non-small cell lung cancer that cannot be removed by surgery and has not progressed after chemotherapy and radiation. The goal is to see which drug works better to keep the cancer from growing.
Daphne, AlabamaAges 18 years+ - NCT04696575RecruitingPhase 2
Lamivudine added to chemoimmunotherapy for extensive-stage lung cancer
This trial tests whether adding lamivudine to standard chemoimmunotherapy can improve outcomes for people with extensive-stage small cell lung cancer. It aims to see if this combination controls the cancer better than standard treatment alone.
Buffalo, New YorkAges 18 years+ - NCT05568212RecruitingPhase 2
Trial of immune combination versus standard care for NSCLC relapse
This Phase 2 trial studies an immune-based drug combination compared with standard care for lung cancer that has come back after chemoradiation and durvalumab. It aims to improve control of the cancer after durvalumab is no longer working.
Roma, RMAges 18 years+ - NCT06483282RecruitingPhase 2
Study of immunotherapy plus targeted therapy and chemo before surgery for lung cancer
This trial tests a combination of immunotherapy (adebrelimab), a targeted therapy (apatinib), and chemotherapy given before surgery for people with limited-stage small cell lung cancer. The goal is to see if this treatment shrinks the tumor enough to make surgery more effective and to study markers that might predict response.
Hangzhou, ZhejiangAges 18–75 - NCT06582771RecruitingPhase 2
Testing sotorasib for untreated lung cancer with KRAS G12C mutation
This trial tests an oral targeted drug called sotorasib for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have not had any prior treatment for their advanced disease. It aims to see if this drug can shrink tumors and help patients without using standard chemotherapy or immunotherapy first.
Basking Ridge, New JerseyAges 18 years+ - NCT06907160Recruiting
Chemotherapy plus immunotherapy before lung cancer surgery
This trial tests a combination of chemotherapy and immunotherapy given before surgery for stage II or III non-small cell lung cancer. Doctors will look at biomarkers in your blood and tissue to see how the cancer responds, which could help guide future treatments.
SeoulAges 19 years+ - NCT07122687RecruitingPhase 2
IBI363 or Pembrolizumab with Chemo before Lung Cancer Surgery
This trial tests two different drug combinations (IBI363 plus chemo versus pembrolizumab plus chemo) given before surgery for people with a specific type of lung cancer. The goal is to see which approach works better at shrinking the tumor and helping patients recover.
Shenyang, LiaoningAges 18–75 - NCT06617936RecruitingPhase 2
Immunotherapy plus endostatin and chemo for stage III lung cancer
This trial tests a combination of an immunotherapy drug (tislelizumab), an anti-angiogenic drug (endostatin), and standard chemotherapy for people with stage III lung cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
Jinan, ShandongAges 18–75
Hear when a new Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer stage iii?
- Yes. Clin2 currently lists 392 recruiting lung cancer stage iii studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer stage iii trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer stage iii trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Non-small Cell Lung Cancer Stage III
- Stage III Lung Cancer AJCC v8
- Nonsmall Cell Lung Cancer Stage III
- Unresectable Stage III Non-small Cell Lung Cancer
- Small Cell Lung Cancer Extensive Stage
- Stage IV Lung Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.